Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (917 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A chronic progressive subcutaneous infection caused by species of fungi (eumycetoma), or actinomycetes (actinomycetoma). It is characterized by tumefaction, abscesses, and tumor-like granules representing microcolonies of pathogens, such as madurella fungi and bacteria actinomycetes, with different grain colors.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Maduromycosis; Eumycetoma; Actinomycetoma; Madura Foot.
Where it fits in the MeSH classification
- Broader topics
- Nocardia Infections; Skin Diseases, Bacterial; Dermatomycoses
Related concepts
- Madurella
- Actinomycetes
Research landscape
PubMed indexes 2,351 records tagged with the MeSH heading “Mycetoma” (counts retrieved 2026-10-29). 291 of them (12.4%) were published from 2020 onward, and the busiest period so far is through 1999 with 1,199 records.
Reviews account for 250 records (10.6%) and meta-analyses for 2. Randomized controlled trials number 6 (0.3%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 1,199 |
| 2000-2009 | 440 |
| 2010-2019 | 421 |
| 2020 onward | 291 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 250 | 10.6% |
| Meta-analyses | 2 | 0.1% |
| Randomized controlled trials | 6 | 0.3% |
Method: PubMed query "Mycetoma"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in infectious diseases
Infectious disease evidence combines microbiology, epidemiology and clinical trials. Laboratory studies identify pathogens and how they cause harm; surveillance and outbreak investigations describe who is affected and how infection spreads; trials establish whether treatments and vaccines work. Results depend on place and time, because pathogens evolve and resistance patterns and population immunity change. Check when and where the data were collected, how cases were defined and how up to date the evidence is.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Global burden of human mycetoma: a systematic review and meta-analysis | 2013 | Meta-analysis Design not recorded in structured metadata | 249 | cc by PMID 24244780 · DOI · PMC3820768 |
| Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan | 2015 | Research article Design not recorded in structured metadata | 119 | cc by PMID 25816316 · DOI · PMC4376889 |
| The global distribution of actinomycetoma and eumycetoma | 2020 | Review article Design not recorded in structured metadata | 95 | cc by PMID 32970667 · DOI · PMC7514014 |
| Mycetoma | 2026 | Review article Design not recorded in structured metadata | 0 | cc by PMID 42139367 · DOI · PMC13178979 |
Global burden of human mycetoma: a systematic review and meta-analysis [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Mycetoma is a chronic infectious disease of the subcutaneous tissue with a high morbidity.
- Closing excerpt
- By erecting (inter)national surveillance programs a more accurate estimation of the global burden on mycetoma can be obtained.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (205 words)
Mycetoma is a chronic infectious disease of the subcutaneous tissue with a high morbidity. This disease has been reported from countries between 30°N and 15°S since 1840 but the exact burden of disease is not known. It is currently unknown what the incidence, prevalence and the number of reported cases per year per country is. In order to estimate what the global burden of mycetoma is, a meta-analysis was performed. In total 50 studies were included, which resulted in a total of 8763 mycetoma cases. Most cases were found in men between 11 and 40 years of age. The foot was most commonly affected. Most cases were reported from Mexico, Sudan and India. Madurella mycetomatis was the most prevalent causative agent world-wide, followed by Actinomadura madurae, Streptomyces somaliensis, Actinomadura pelletieri, Nocardia brasiliensis and Nocardia asteroides. Although this study represents a first indication of the global burden on mycetoma, the actual burden is probably much higher. In this study only cases reported to literature could be used and most of these cases were found by searching archives from a single hospital in a single city of that country. By erecting (inter)national surveillance programs a more accurate estimation of the global burden on mycetoma can be obtained.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 24244780 · DOI · PMC3820768
Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan [2]
Abstract reading summary — source excerpts
- Opening excerpt
- This communication reports on the Mycetoma Research Centre of the University of Khartoum, Sudan experience on 6,792 patients seen during the period 1991-2014.
- Closing excerpt
- 7%).
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (313 words)
This communication reports on the Mycetoma Research Centre of the University of Khartoum, Sudan experience on 6,792 patients seen during the period 1991-2014.The patients were predominately young (64% under 30 years old) males (76%). The majority (68%) were from the Sudan mycetoma belt and 28% were students. Madurella mycetomatis eumycetoma was the most common type (70%). In 66% of the patients the duration of the disease was less than five years, and 81% gave a history of sinuses discharging mostly black grains (78%). History of trauma at the mycetoma site was reported in 20%. Local pain was reported in 27% of the patients, and only 12% had a family history of mycetoma. The study showed that 57% of the patients had previous surgical excisions and recurrence, and only 4% received previous medical treatment for mycetoma. Other concomitant medical diseases were reported in 4% of the patients. The foot (76%) and hand (8%) were the most commonly affected sites. Less frequently affected sites were the leg and knee (7%), thigh (2%), buttock (2%) and arm and forearm (1%). Rare sites included the chest wall, head and neck, back, abdominal wall, perineum, oral cavity, tongue and eye. Multiple sites mycetoma was recorded in 135 (2%) of cases. At presentation, 37% of patients had massive lesions, 79% had sinuses, 8% had local hyper-hydrosis at the mycetoma lesion, 11% had regional lymphadenopathy, while 6% had dilated tortuous veins proximal to the mycetoma lesions. The diagnosis of mycetoma was established by combined imaging techniques and cytological, histopathological, serological tests and grain culture. Patients with actinomycetoma received a combination of antimicrobial agents, while eumycetoma patients received antifungal agents combined with various surgical excisions. Surgical excisions in the form of wide local excision, debridement or amputation were done in 807 patients, and of them 248 patients (30.7%) had postoperative recurrence. Different types of amputations were done in 120 patients (1.7%).
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25816316 · DOI · PMC4376889
The global distribution of actinomycetoma and eumycetoma [3]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundMycetoma, a chronic infection of the skin and underlying structures, affects those with a close relationship to the land, often in resource-poor areas of the world.
- Closing excerpt
- ConclusionsWith better understanding of the epidemiology of mycetoma, more can be done to direct education, preventive measures, and treatment to at-risk areas, enabling a reduction in disease burden.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (235 words)
BackgroundMycetoma, a chronic infection of the skin and underlying structures, affects those with a close relationship to the land, often in resource-poor areas of the world. Whether caused by any one of a variety of fungus or bacteria, mycetoma causes significant disability and mortality. Acknowledged as a neglected tropical disease (NTD) by the World Health Organization (WHO) in 2016, mycetoma is susceptible to being misunderstood, misdiagnosed, and mismanaged. In an effort to shift the balance in favor of recognition and effective treatment, sound epidemiological understanding is required.Methods and findingsIn this paper, a literature review of case reports and series (332 papers in total) is presented as three maps. We identified 19,494 cases dating from 1876 to 2019, with cases contracted in 102 countries. The first map shows where mycetoma has ever been reported, the second shows how many cases have been reported, and the third shows the ratio of eumycetoma (fungal) to actinomycetoma (bacterial). Most cases are found in Mexico, India, and Sudan, where mycetoma is studied rigorously. We identified emergence of new geographical loci, including the United States, Venezuela, Italy, China, and Australia. Notably, mycetoma is reported far outside the tropics. In the Americas, bacterial forms dominate, whereas, in Africa and Asia, the picture is more varied.ConclusionsWith better understanding of the epidemiology of mycetoma, more can be done to direct education, preventive measures, and treatment to at-risk areas, enabling a reduction in disease burden.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 32970667 · DOI · PMC7514014
Mycetoma [4]
Abstract reading summary — source excerpts
- Opening excerpt
- The Neglected Tropical Disease mycetoma is a chronic, progressive infectious disease characterized by large tumor-like masses in subcutaneous tissues.
- Closing excerpt
- Although the recognition of mycetoma as both a neglected tropical disease and a fungal priority pathogen has increased awareness and research interest, large knowledge gaps remain.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (164 words)
The Neglected Tropical Disease mycetoma is a chronic, progressive infectious disease characterized by large tumor-like masses in subcutaneous tissues. It is endemic in rural areas of low- and middle-income countries, where it can lead to extensive health and socioeconomic burdens for the patient and their family. It is especially prevalent among male farmers. The disease can be caused by both bacteria and fungi, referred to as actinomycetoma and eumycetoma, respectively. Inoculation occurs when a skin breach allows the pathogen to enter the subcutaneous tissue. The pathogen can form grains, which make the disease more resistant to host defense and antimicrobial treatments. This review summarizes the current knowledge on the historical background and epidemiology of mycetoma, the characteristics of its causative agents, underlying pathophysiology, diagnostic approaches, available treatment strategies, preventive measures, and future prospects for disease management and research. Although the recognition of mycetoma as both a neglected tropical disease and a fungal priority pathogen has increased awareness and research interest, large knowledge gaps remain.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42139367 · DOI · PMC13178979
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Infections caused by Scedosporium spp [5]
- Research article Disseminated phaeohyphomycosis: review of an emerging mycosis [6]
- Research article Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist [7]
- Research article Mycetoma: a unique neglected tropical disease [8]
- Research article Mycetoma: a thorn in the flesh [9]
- Research article Mycetoma caused by Madurella mycetomatis: a neglected infectious burden [10]
References
- van de Sande WW. Global burden of human mycetoma: a systematic review and meta-analysis. . 2013. PMID 24244780 · DOI · PMC3820768
- Fahal A, Mahgoub el S, El Hassan AM, Abdel-Rahman ME. Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan. . 2015. PMID 25816316 · DOI · PMC4376889
- Emery D, Denning DW. The global distribution of actinomycetoma and eumycetoma. . 2020. PMID 32970667 · DOI · PMC7514014
- Hoekstra M, Lattwein KR, van de Sande WWJ. Mycetoma. . 2026. PMID 42139367 · DOI · PMC13178979
- Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T, et al.. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008. PMID 18202441 · DOI · PMC2223844
- Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis. 2002. PMID 11797173 · DOI
- Guarro J, Kantarcioglu AS, Horré R, Rodriguez-Tudela JL, Cuenca Estrella M, Berenguer J, et al.. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol. 2006. PMID 16772225 · DOI
- Zijlstra EE, van de Sande WWJ, Welsh O, Mahgoub ES, Goodfellow M, Fahal AH. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis. 2016. PMID 26738840 · DOI
- Fahal AH. Mycetoma: a thorn in the flesh. Trans R Soc Trop Med Hyg. 2004. PMID 14702833 · DOI
- Ahmed AO, van Leeuwen W, Fahal A, van de Sande W, Verbrugh H, van Belkum A. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. 2004. PMID 15336224 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.